Search

Philip Sherratt Phones & Addresses

  • 7 Marion Ln, Scotch Plains, NJ 07076
  • 25 Paterson Rd, Fanwood, NJ 07023 (908) 322-1461
  • Springfield, NJ
  • 28 North Ave, Cranford, NJ 07016 (908) 272-1370
  • Union, NJ
  • 28 North Ave W, Cranford, NJ 07016 (908) 229-3632

Work

Company: Celgene May 2010 Position: Director of toxicology

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Dundee 1995 to 1998 Specialities: Biochemistry, Toxicology

Industries

Pharmaceuticals

Public records

Vehicle Records

Philip Sherratt

View page
Address:
25 Paterson Rd, Fanwood, NJ 07023
Phone:
(908) 322-1461
VIN:
KNDMC233576024067
Make:
HYUNDAI
Model:
ENTOURAGE
Year:
2007

Resumes

Resumes

Philip Sherratt Photo 1

Director Of Toxicology

View page
Location:
New York, NY
Industry:
Pharmaceuticals
Work:
Celgene
Director of Toxicology

Merck Nov 2009 - May 2010
Toxicologist

Schering-Plough Research Institute Oct 2004 - Nov 2009
Toxicologist

Schering-Plough Research Institute Oct 2001 - Sep 2004
Post-Doctoral Research Scientist

University of Dundee Oct 1998 - Sep 2001
Post-Doctoral Scientist
Education:
University of Dundee 1995 - 1998
Doctorates, Doctor of Philosophy, Biochemistry, Toxicology
Nottingham University Business School 1992 - 1995
Bachelors, Bachelor of Science, Biochemistry, Chemistry
Cheadle High School
Dundee University

Publications

Us Patents

Methods For Screening Cereblon Modifying Compounds

View page
US Patent:
20190219562, Jul 18, 2019
Filed:
Jan 10, 2019
Appl. No.:
16/244667
Inventors:
- Summit NJ, US
Philip Chamberlain - San Diego CA, US
Suzana Sturlini Couto - La Jolla CA, US
Katherine Stamp - Montclair NJ, US
Philip J. Sherratt - Scotch Plains NJ, US
Gang Lu - San Diego CA, US
Julia Hui - Basking Ridge NJ, US
Assignee:
CELGENE CORPORATION - Summit NJ
International Classification:
G01N 33/50
Abstract:
A method of screening a cereblon modifying compound for treating a disease or disorder, comprising: obtaining a sample; determining a first protein level of SALL4; administering the cereblon modifying compound to the sample; determining a second protein level of SALL4; comparing the first level and the second protein level of SALL4 to determine if the cereblon modifying compound induces degradation of SALL4; and selecting the cereblon modifying compound that does not induce degradation of SALL4.
Philip J Sherratt from Scotch Plains, NJ, age ~51 Get Report